Plain-English translation of NCT05987644 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a targeted medication for people with a specific type of lung cancer (one with ALK rearrangements) that has spread to the brain. The study has two main questions: Does the medication work well on its own, or does it work better when combined with radiation therapy to the brain? Researchers want to help patients and doctors decide the best treatment approach.
When lung cancer spreads to the brain, doctors traditionally treat it with radiation right away. However, this new medication is very effective against this specific type of cancer, and researchers want to know whether radiation can be delayed or even skipped entirely, which would reduce side effects while keeping patients healthy.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth twice daily for up to 2 years (in 28-day cycles). Depending on which group you're assigned to, you may receive focused radiation to your brain tumors first, then start the medication 1–7 days later, or you may start the medication alone without radiation. You'll have regular check-ins with your medical team, including imaging scans and blood work, to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States